share_log

Pfizer | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Pfizer Inc. (“Pfizer”)(0.0%)

Pfizer | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Pfizer Inc. (“Pfizer”)(0.0%)

輝瑞 | SC 13D/A:超過5%持股股東披露文件(修正)-Pfizer Inc. (“Pfizer”)(0.0%)
美股SEC公告 ·  08/05 18:12

Moomoo AI 已提取核心訊息

On August 1, 2024, Pfizer Inc. reported the completion of a merger between Cerevel Therapeutics Holdings, Inc. and Symphony Harlan Merger Sub Inc., a subsidiary of AbbVie Inc. The merger resulted in Cerevel becoming a wholly owned subsidiary of AbbVie. At the effective time of the merger, each share of Cerevel's common stock was converted into the right to receive $45.00 per share in cash, excluding certain specified shares. This transaction was finalized as disclosed in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission. Following the merger, Cerevel's common stock ceased trading on The Nasdaq Capital Market and was delisted. Pfizer, which had beneficially owned shares in Cerevel, reported owning 0 shares post-merger, marking this filing as an 'exit filing' for the company.
On August 1, 2024, Pfizer Inc. reported the completion of a merger between Cerevel Therapeutics Holdings, Inc. and Symphony Harlan Merger Sub Inc., a subsidiary of AbbVie Inc. The merger resulted in Cerevel becoming a wholly owned subsidiary of AbbVie. At the effective time of the merger, each share of Cerevel's common stock was converted into the right to receive $45.00 per share in cash, excluding certain specified shares. This transaction was finalized as disclosed in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission. Following the merger, Cerevel's common stock ceased trading on The Nasdaq Capital Market and was delisted. Pfizer, which had beneficially owned shares in Cerevel, reported owning 0 shares post-merger, marking this filing as an 'exit filing' for the company.
2024年8月1日,輝瑞公司報道了輝瑞、Symphony Harlan Merger Sub公司和Cerevel Therapeutics Holdings公司之間合併的完成,Symphony Harlan Merger Sub公司是艾伯維公司的子公司。合併後,Cerevel成爲艾伯維的全資子公司。在合併生效時,Cerevel的普通股每股轉換成現金獲取$45,某些特定股份除外。該交易已經在向美國證券交易委員會提交的當前8-K表格中披露並正式完成。在合併後,Cerevel的普通股停止在納斯達克資本市場交易,並被除牌。曾有過Cerevel股份的輝瑞公司報告,在合併後不再持有Cerevel的股份,標誌着對該公司的“退出申報”。
2024年8月1日,輝瑞公司報道了輝瑞、Symphony Harlan Merger Sub公司和Cerevel Therapeutics Holdings公司之間合併的完成,Symphony Harlan Merger Sub公司是艾伯維公司的子公司。合併後,Cerevel成爲艾伯維的全資子公司。在合併生效時,Cerevel的普通股每股轉換成現金獲取$45,某些特定股份除外。該交易已經在向美國證券交易委員會提交的當前8-K表格中披露並正式完成。在合併後,Cerevel的普通股停止在納斯達克資本市場交易,並被除牌。曾有過Cerevel股份的輝瑞公司報告,在合併後不再持有Cerevel的股份,標誌着對該公司的“退出申報”。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息